EX9 Stock Price, Chart, Stats & News

Exelixis, Inc. operates as a biotechnology firm primarily dedicated to combating cancer through the discovery, development, and commercialization of novel therapeutic agents within the United States. Its current product portfolio features CABOMETYX tablets, prescribed for patients with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, used to manage progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are derived from cabozantinib, a potent inhibitor targeting various tyrosine kinases, including MET, AXL, RET, and VEGF receptors.